Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) that inhibits COX-1 and COX-2. Lornoxicam exhibits both anti-inflammatory and analgesic activities. In vivo, lornoxicam decreases herpetic stromal keratitis induced by herpes simplex virus HSV-1 by decreasing activation of NF-κB and expression of TNF-α. In other animal models, lornoxicam decreases levels of prostaglandin E2 (PGE2) and attenuates Freund’s adjuvant-induced hyperalgesia. Lornoxicam also exhibits some antioxidative and neuroprotective activities, decreasing caspase 3 activity and malondialdehyde levels and increasing superoxide dismutase (SOD) levels to prevent neuronal apoptosis in animal models of brain injury.